Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly ICLC in Recurrent Anaplastic Glioma
NCT00058123Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2003
- Primary completion
- Oct 2007
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poly iclc in anaplastic glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Objective Response Rate at 2 years and Progression Free Survival at 6 months. Started Mar 2003; status: completed.
02
Drugs
poly iclc
03
Conditions
anaplastic glioma
Beyond the preview
Go deeper on NCT00058123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058123.